Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 2
1954 1
1957 1
1959 1
1961 1
1962 2
1963 1
1964 1
1965 3
1966 4
1967 9
1968 6
1969 6
1970 2
1971 3
1972 5
1973 6
1974 2
1975 3
1976 6
1977 5
1978 2
1979 1
1980 3
1981 1
1983 1
1984 7
1985 4
1986 3
1987 3
1988 4
1989 6
1990 9
1991 10
1992 7
1993 13
1994 15
1995 13
1996 19
1997 9
1998 17
1999 15
2000 15
2001 18
2002 15
2003 17
2004 23
2005 25
2006 33
2007 26
2008 20
2009 29
2010 44
2011 46
2012 49
2013 38
2014 58
2015 65
2016 69
2017 60
2018 64
2019 65
2020 86
2021 114
2022 106
2023 108
2024 120
2025 132

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,521 results

Results by year

Filters applied: . Clear all
Page 1
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E, Altorki N, Zhou C, Vallières E, Martínez-Martí A, Rittmeyer A, Chella A, Reck M, Goloborodko O, Huang M, Belleli R, McNally V, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA. Felip E, et al. Among authors: srivastava mk. Ann Oncol. 2023 Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17. Ann Oncol. 2023. PMID: 37467930 Free article. Clinical Trial.
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, Gayevskiy V, Elhossiny AM, Srivastava MK, Patil NS, Smith KA, Jesudason R, Chan C, Chang PS, Fernandez M, Rost S, McGinnis LM, Koeppen H, Gay CM, Minna JD, Heymach JV, Chan JM, Rudin CM, Byers LA, Liu SV, Reck M, Shames DS. Nabet BY, et al. Among authors: srivastava mk. Cancer Cell. 2024 Mar 11;42(3):429-443.e4. doi: 10.1016/j.ccell.2024.01.010. Epub 2024 Feb 15. Cancer Cell. 2024. PMID: 38366589 Free article.
Developmental and stem cell biology's bright future.
Lewis J, Schuh M, Hanna JH, Zernicka-Goetz M, Srivastava M, Tan T, Behjati S, Liu Z, Petridou NI, Mendjan S. Lewis J, et al. Among authors: srivastava m. Cell. 2024 Jun 20;187(13):3224-3228. doi: 10.1016/j.cell.2024.05.037. Cell. 2024. PMID: 38906097 Free article.
Citicoline in acute ischemic stroke: A randomized controlled trial.
Agarwal A, Vishnu VY, Sharma J, Bhatia R, Garg A, Dwivedi S, Upadhyay A, Goyal V, Singh MB, Gupta A, Rajan R, Srivastava MVP. Agarwal A, et al. Among authors: srivastava mvp. PLoS One. 2022 May 31;17(5):e0269224. doi: 10.1371/journal.pone.0269224. eCollection 2022. PLoS One. 2022. PMID: 35639720 Free PMC article. Clinical Trial.
Preface.
Goldstein B, Srivastava M. Goldstein B, et al. Among authors: srivastava m. Curr Top Dev Biol. 2022;147:xvii-xviii. doi: 10.1016/S0070-2153(22)00040-0. Curr Top Dev Biol. 2022. PMID: 35337469 No abstract available.
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study Investigators. Felip E, et al. Among authors: srivastava mk. J Clin Oncol. 2025 Jul 20;43(21):2343-2349. doi: 10.1200/JCO-24-01681. Epub 2025 May 30. J Clin Oncol. 2025. PMID: 40446184 Clinical Trial.
Organoid culture promotes dedifferentiation of mouse myoblasts into stem cells capable of complete muscle regeneration.
Price FD, Matyas MN, Gehrke AR, Chen W, Wolin EA, Holton KM, Gibbs RM, Lee A, Singu PS, Sakakeeny JS, Poteracki JM, Goune K, Pfeiffer IT, Boswell SA, Sorger PK, Srivastava M, Pfaff KL, Gussoni E, Buchanan SM, Rubin LL. Price FD, et al. Among authors: srivastava m. Nat Biotechnol. 2025 Jun;43(6):889-903. doi: 10.1038/s41587-024-02344-7. Epub 2024 Sep 11. Nat Biotechnol. 2025. PMID: 39261590 Free PMC article.
Cell cycle progression of under-replicated cells.
Huang M, Yang C, Nie L, Zhang H, Zhu D, Wang C, Park JM, Srivastava M, Mosa E, Li S, Tang M, Feng X, Keast SJ, Stossi F, Chen J. Huang M, et al. Among authors: srivastava m. Nucleic Acids Res. 2025 Jan 7;53(1):gkae1311. doi: 10.1093/nar/gkae1311. Nucleic Acids Res. 2025. PMID: 39778868 Free PMC article.
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.
Zhou C, Dong X, Chen G, Wang Z, Wu X, Yao Y, Zhang Y, Cheng Y, Pan H, Zhang X, Cui J, Wang L, Chen X, Li X, Wang Z, Wang Q, He J, Wang M, Yan I, Qian L, Xu M, Huang X, Sun C, Cai J, Wu Q, Ballinger M, Kaul M, Srivastava MK. Zhou C, et al. Among authors: srivastava mk. Nat Med. 2025 Jul;31(7):2375-2384. doi: 10.1038/s41591-025-03658-y. Epub 2025 May 16. Nat Med. 2025. PMID: 40379995 Free PMC article. Clinical Trial.
1,521 results